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AbstrACt
Objective Cancer is a leading killer worldwide, including 
Australia. Cancer diagnosis leads to a substantial burden 
on the individual, their family and society. The main aim 
of this study is to understand the trends, determinants 
and inequalities associated with cancer incidence, 
hospitalisation, mortality and its burden over the period 
1982 to 2014 in Australia.
settings The study was conducted in Australia.
study design An incidence- based study design was used.
Methods Data came from the publicly accessible 
Australian Institute of Health and Welfare database. 
This contained 2 784 148 registered cancer cases over 
the study period for all types of cancer. Erreygers’ 
concentration index was used to examine the magnitude 
of socioeconomic inequality with regards to cancer 
outcomes. Furthermore, a generalised linear model was 
constructed to identify the influential factors on the overall 
burden of cancer.
results The results showed that cancer incidence (annual 
average percentage change, AAPC=1.33%), hospitalisation 
(AAPC=1.27%), cancer- related mortality (AAPC=0.76%) 
and burden of cancer (AAPC=0.84%) all increased 
significantly over the period. The same- day (AAPC=1.35%) 
and overnight (AAPC=1.19%) hospitalisation rates also 
showed an increasing trend. Further, the ratio (least- most 
advantaged economic resources ratio, LMR of mortality 
(M) and LMR of incidence (I)) was especially high for 
cervix (M/I=1.802), prostate (M/I=1.514), melanoma (M/
I=1.325), non- Hodgkin's lymphoma (M/I=1.325) and 
breast (M/I=1.318), suggesting that survival inequality was 
most pronounced for these cancers. Socioeconomically 
disadvantaged people were more likely to bear an 
increasing cancer burden in terms of incidence, mortality 
and death.
Conclusions Significant differences in the burden of 
cancer persist across socioeconomic strata in Australia. 
Policymakers should therefore introduce appropriate 
cancer policies to provide universal cancer care, which 
could reduce this burden by ensuring curable and 
preventive cancer care services are made available to all 
people.
bACkgrOund
Non- communicable diseases (NCDs) are 
accountable for the majority of global deaths.1 
Cancer is expected to rank as the most signif-
icant global public health problem and a 
leading cause of death and illness in the world 
in the 21st century2–6 including Australia.7 In 
2019, it is estimated that almost 145 000 new 
cases of cancer will be diagnosed in Australia, 
and 35% of these individuals will eventually 
die from the disease.7 Cancer accounts for 
the highest burden of disease of any illness, at 
approximately 18% (19% for males; 17% for 
females), followed by cardiovascular disease 
(14%), musculoskeletal (13%) and mental 
health (12%).8 Approximately 40% of cancer 
patients are of working age in Australia.7 
Among those in employment, 46% are unable 
to return to work after an episode,9 and 67% 
return to employment or change their job 
after being diagnosed.10 The majority of 
strengths and limitations of this study
 ► This study examined the trends, determinants and 
inequality in terms of incidence, mortality, hospital-
isation and associated burden of cancer (eg, years 
life lost, years lost due to disability and disability- 
adjusted life years) in the Australian context over a 
33 year period.
 ► This study was not captured in details inequalities 
regarding the cancer survivorship in terms of stage, 
treatment procedures and utilisation of healthcare.
 ► Although we have limited understanding of what is 
driving these changes in cancer outcomes as report-
ed here they may reflect random variation or chang-
es in unknown risk factors, and therefore highlight 
the need for more research into the aetiology of 
cancer.
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cancer survival patients depend on family, relatives and 
friends for physical and economical support during their 
treatment and/or in the last stages of the disease.9–12 
Cancer- related illness results in a substantial number of 
patients experiencing economical hardship due to high 
out- of- pocket expenses (eg, medicines and treatments, 
including diagnostics), lost productivity, loss/reduc-
tion of household income and other induced expendi-
ture.9 10 12 13 The economic burden of cancer is of growing 
concern for policymakers, healthcare practitioners, physi-
cians, employers and society overall.10 12 Furthermore, the 
magnitude of the cancer burden increases significantly 
with remoteness from treatment sources and those indi-
viduals in depressed socioeconomic circumstances.14–16 
Considerable progress has been made in recent decades 
in terms of cancer survival and reduced mortality rates17 18 
through several initiatives including introducing primary 
preventive strategies and effective collaboration with 
non- government organisations and other stakeholders. 
Therefore, a reduction of cancer incidence, along with 
improvements in cancer treatments and therefore survival 
rates, are essential to reduce the burden of the disease.
Economic disparities between socioeconomically advan-
taged and disadvantaged individuals and groups are wors-
ened by the increasing burden of cancer in Australia.15 
The lack of appropriate services are significantly worse 
in resource- poor settings, including geographically disad-
vantaged areas compared with more advantaged people 
and communities with easier access to a greater range 
of cancer services, increased knowledge and awareness 
of cancer prevention and better and more easily acces-
sible health facilities and resources.15 19 20 Other common 
reasons for such disparities include limited affordability 
and accessibility of cancer care services for individuals 
from socioeconomically disadvantaged groups,16 and their 
inadequate utilisation of healthcare.21 Thus, increased 
cancer incidence leads to a higher overall burden for the 
individual, family and society, which is exacerbated for 
the more disadvantaged.
In the recent past, disparities related to cancer 
outcomes have become the subject of international focus 
and new service initiatives.2 6 In 2016, the WHO Executive 
Board recommendation was to strengthen health systems 
to ensure early detection and diagnosis, as well as acces-
sible, affordable and appropriate and quality healthcare 
services for all patients with cancer.22 Only a few studies 
have focused explicitly on socioeconomic inequality of 
cancer care and healthcare utilisation in Australia. This 
study therefore purposes to provide data and analysis on 
trends in cancer incidence, mortality rates, hospitalisation 
and associated burden (years life lost, YLL; years lost due 
to disability, YLD and disability- adjusted life years, DALYs) 
for the most prevalent malignancies among Australians, 
by sex, state, remoteness and socioeconomic status, using 
routinely collected health data for the period of 1982 to 
2014.
There is an extensive body of research on the many 
different dimensions of cancer. In recent decades, the 
cancer incidence has increased,5 17 23–25 which has been 
more pronounced among adolescents and young adults,26 
and older adults,27 yet cancer- related mortality rates have 
slightly dropped.28 Some types of cancer in Australia are 
the highest in the world: melanoma,26 keratinocyte and 
melanocyte.29 Australia and New Zealand together have 
the highest rates for Merkel cell carcinoma.30 31 A number 
of studies have focused on geographical or socioeconomic 
disparities in cancer care and survival.32–38 These have 
usually been conducted in small settings at the Austra-
lian state level. No previous studies have attempted to 
measure the trends, associated determinants and magni-
tude of socioeconomic inequalities of cancer outcomes 
(eg, incidence, mortality, hospitalisation and burden of 
cancer - YLL, YLD, DALYs) over time. Therefore, national 
level trends, the differential socioeconomic inequality of 
cancer outcomes, as well as influential factors associated 
with the cancer burden in Australia are unclear.
Furthermore, the study’s findings will provide authori-
ties with national evidence about the trends and magni-
tude of the inequalities in cancer burden and hopefully 
assist in developing low- cost interventions to reduce this 
burden. This study thus aims to examine the trends, asso-
ciated determinants and magnitude of socioeconomic 
inequality as related to incidence, mortality, YLL, YLD 
and DALYs, as a result of cancer.
MethOds
study design
An incidence- based approach was used to examine the 
trends and socioeconomic inequalities associated with 
adverse cancer outcomes in Australia. A health system 
perspective was adopted and cancer- related data were 
accessed from organisations that are committed to 
promote, restore or maintain health and well- being.39 40 
The study population represented different population 
subgroups using characteristics such as sex, geographical 
distribution and economic circumstances.
Australian health system
Australian health system (AHS) provides quality and 
affordable healthcare services for all Australians. It is oper-
ated by three levels of government: federal (financing), 
state and territory (funding and service delivery) and 
local (service delivery).41 The foundation of AHS is the 
publically funded national universal health insurance 
scheme, Medicare and its predecessor Medibank which 
commenced in the 1970s to promote universal health-
care by providing safe and affordable healthcare services 
for Australians. Through Medicare, patients are able to 
access medical services, treatment in public hospitals free 
of charge, receive subsidised out of hospital treatment and 
medicines. Those eligible to access healthcare services 
through Medicare include: Australian and New Zealand 
citizens, permanent residents of Australia and individuals 
who have applied for a permanent visa.42 On the other 
hand, overseas student health cover is mandatory for all 
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international students, to ensure they and their depen-
dents can access affordable healthcare while living and 
studying in Australia. Patients are provided a rebate 
benefit for healthcare services for out of hospital services.
The rebate amount is case dependent. For example, for 
a consultation with a general practitioner (GP), specialist 
or consultant physician of at least 10 min duration on a 
patient with cancer to develop a multidisciplinary treat-
ment plan, the schedule payment is $A81.50 in 2019, 
and the benefit is 100% of the schedule fee; hyperbaric 
oxygen therapy associated with treatment of localised 
non- neurological soft tissue radiation injuries has a 
schedule fee of $A254.75 and the benefit is 75% of the 
schedule fee, or $A191.10.42 While public hospitals are 
free of charge, the majority of out of hospital healthcare 
services are provided by private health providers. The 
actual amount of fees for service is set by the providers 
themselves and are not regulated, meaning that private 
healthcare providers can make their fees above the 
schedule payment. Any difference between the amount of 
the providers fee for a service and the amount of rebate 
is paid by the patient from their out- of- pocket (OOP). 
For example, if the actual amount charged of a provider 
is $A81.50 for a diagonostic (eg, blood) test, Medicare 
would provide a rebate of $A69.30 (75% of the schedule 
fee), leaving the patient to pay $A12.20. Medicare has 
additional policies to protect patients from catatrophic 
OOP healthcare payments. In this context, healthcare 
cards are provided to welfare recipients and low income 
earners, and other eligible patients who pay a lower 
OOP payment for prescription medicines.43 The ‘Medi-
care Safety Net’ and ‘Extended Medicare Safety Net’ 
Programmes also provide higher rebates if an individual 
or family group reaches a certain level of total expendi-
ture on OOP fees within a calendar year. Any subsequent 
services or prescriptions will have a higher proportion 
subsidised for the rest of that calendar year.44 Under the 
‘Medicare Safety Net’, once the threshold is reached then 
100% of the schedule fee for all healthcare services is 
rebated; and under the ‘Extended Medicare Safety Net’ 
80% of the actual OOP payments are rebated.45
data sources
Various cancer- related national data sources were 
accessed. Data on cancer incidence, mortality and hospi-
talisation were extracted from the publicly accessible 
Australian Institute of Health and Welfare (AIHW) online 
database7 and cancer- related published reports.8 46 AIHW 
accumulates data from the Australian Cancer Database 
(ACD), National Mortality Database (NMD) and National 
Hospital Morbidity Database (NHMD). ACD accumulates 
and manages all sorts of cancer data from each Austra-
lian state and territory under legal mandate since 1982. 
Different types of hospitals (eg, government and non- 
government), clinics, laboratories other organisations and 
institutions are required to report all cancer cases to the 
central cancer registry (CCR). The CCR data is delivered 
to the AIHW on an annual basis, where it is accumulated 
into the ACD. The NMD includes information supplied 
by the registries of births, deaths and marriages and the 
national coronial information system. These data are 
then coded by the Australian Bureau of Statistics (ABS) 
and are incorporated into the NMD. The NHMD is an 
accumulation of episode- level records of hospitalised 
patient morbidity data collection systems (eg, all acute 
and psychiatric hospitals, freestanding day hospital facil-
ities and alcohol and drug treatment centres). Further, 
cancer burden- related data is collected via the Australian 
Burden of Disease Study (ABDS). Data were retrieved 
from the published reports of ABDS-2011 and ABDS-
2015, the last two that explicitly included cancer.8 46 Death 
caused by cancer was considered as the fatal burden (eg, 
YLL) and this data was sourced from the NMD. The non- 
fatal cancer burden related data emanated from different 
administrative sources including NHMD, ACD, NMD and 
some epidemiological studies. ABDS amassed data on 
some other parameters from the Global Burden of Disease 
studies of 2010 and 2013 that covered the standard life 
table for fatal burden (YLL), health status and disability 
weights for the non- fatal burden (YLD) and relative risks 
and the risk factor attribution.8 46 The present study used 
these national level accumulated data in the analysis.
study population
A total of 2 784 148 registered cancer cases (male=1 
537 882; female=1 246 265) were accessed, based on 
data from 1982 to 2014 in Australia (table 1). In addi-
tion, to revealing the trends of cancer- related mortality 
over the same period, a total of 1 165 552 cancer- related 
deaths (male=6 59 105; female=5 06 447) were consid-
ered. Due to the paucity and availability of data related 
to cancer outcomes, a total of 591 631 registered cancer 
cases during the period from 2008 to 2012 and a total 
of 217 349 cancer- related deaths during 2010 to 2014 
were used to examine inequality in cancer incidence and 
cancer- related mortality in Australia.
Measurement of cancer parameters
The age- standardised cancer incidence, or mortality rate, 
was measured using the number of new cases diagnosed 
or deaths for a specific age group, divided by the mid- 
year population of the same age group and year. Simi-
larly, cancer incidence or mortality rate was estimated 
from the total number of new cases diagnosed or deaths 
across all age groups combined, divided by the mid- year 
population. These rates were interpreted as the number 
of new cases of cancer or deaths per 100 000 population. 
Cancer related burden estimation was undertaken using 
the burden of disease methodology.8 46 In the ABDS, the 
burden of cancer was calculated through the DALY by 
summing up the fatal burden (ie, YLL) due to premature 
cancer- related mortality and the non- fatal burden (ie, 
YLD) for patients surviving the condition.
 DALY = YLL + YLD  (1)
 YLL =
N
r (1− e−rL) (2)
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Table 1 Characteristics of the study parameters
Parameters Conceptual issues Sample population Period Data sources
Cancer incidence To examine the trends of 
cancer outcomes
2 784 148 1982–2014 ACD
Cancer- related mortality 1 165 552 1982–2014 NMD
Cancer burden (eg, YLL, 
YLD, DALYs)
ABDS population 2011–2015 ABDS
Number of cancer- related 
hospitalisations
13 213 340 2000–2015 NHMD
Cancer incidence To measure the magnitude 
of socioeconomic 
inequalities in terms of 
cancer outcomes and 
cancer burden
591 631 2008–2012 ACD
Cancer- related mortality 217 349 2010–2014 NMD
Cancer burden (eg, YLL, 
YLD, DALYs)
ABDS population 2011–2015 ABDS
Cancer burden (eg, YLL, 
YLD, DALYs)
To investigate associated 
determinants on cancer 
burden over the period
ABDS population 2011–2015 ABDS
ABDS, Australian Burden of Disease Study; ACD, Australian Cancer Database; DALYs, disability- adjusted life years; NHMD, National Hospital 
Morbidity Database; NMD, National Mortality Database; YLD, years lost due to disability; YLL, years life lost.
 
YLD = I × DW× L
(
1−e−rL
r
)
 (3)
Where, n=number of deaths; L (YLL)=standard life 
expectancy at the age of death in that year; I=number of 
people with each type of cancer cases; DW=disability wt; 
r=discount rate; L (YLD)=duration of disability in years.
definition of some potential factors
 Index of economic resources
The magnitude of inequality in cancer outcomes was 
examined using an index of relative socioeconomic 
disadvantage (IRSD). The IRSD was developed by the 
ABS using potential factors like average household 
income, education level and unemployment rates.47 It is a 
geographical area- based estimate of socioeconomic status 
where small geographical settings of Australia are catego-
rised from economically disadvantaged to wealthy. This 
index is employed as a proxy for the socioeconomic status 
of the people living in different geographical settings in 
Australia. The cut- offs value for each of the quintiles are 
as follows: Q1 (IRSD ≤927.0), Q2 (927.0> IRSD ≤965.8), 
Q3 (965.8> IRSD ≤1001.8), Q4 (1001.8> IRSD ≤1056.0) or 
Q5 (IRSD >1056.0).
47 The most disadvantaged socioeco-
nomic quantile (Q1) corresponds to geographical settings 
covering the 20% of the population with least advantaged 
socioeconomic areas, and the fifth quintile (Q5) refers 
to the 20% of the population with the most advantaged 
socioeconomic areas.
 Remoteness
Remote locations exist in each state and territory of 
Australia and are based on the accessibility to services and 
Remoteness Index of Australia, which is constructed by 
the Australian Population and Migration Research Centre 
at the University of Adelaide.48 Remoteness was classi-
fied into six groups: major cities, inner regional, outer 
regional, remote, very remote and migratory. Migratory 
was excluded from the current analysis due to the paucity 
of information. The category of the major cities included 
Australia’s capital cities, except Darwin and Hobart, 
which were treated as an inner regional.
data analysis
 Trend analysis
Trend analysis of cancer incidence, cancer- related 
mortality rates, hospitalisations and burden of cancer 
were performed using the ACD (from 1982 to 2014), 
NMD (1982 to 2014), NHMD (2000 to 2015) and ABDS 
(2011 to 2015) population data sets, respectively. Trend 
analyses were done across sex, state and socioeconomic 
status over these periods. To identify changes in cancer 
parameters trends, joinpoint regression analysis was 
performed using the Joinpoint Regression Programs, 
V.4.5.0.1.49 The annual percentage change (APC) in rates 
between trend- change points (ie, joinpoint segment) 
was calculated, and it also estimated the average annual 
percentage change (AAPC) in the whole study period. 
A negative APC indicates a decreasing trend whereas a 
positive APC indicates an increasing trend. Furthermore, 
increased or decreased APC of cancer- related outcomes 
were examined by the magnitude of cancer’s impact over 
the period.
To measure the APC, the following model was used:
 log(Yx) = b0 + b1x  (4)
where, log (Yx) is the natural logarithm of the rate in 
year x. Then, the APC from year ‘x’ to year ‘x+1’ was:
 APC =
eb0+b1
(
x+1
)
−eb0+b1x
eb0+b1x × 100 =
(
eb1 − 1
)
× 100 (5)
Then, AAPC was estimated as a weighted average of 
the estimated APC in each segment by using the segment 
lengths as weights.
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AAPC =
(
e
∑(Si×APCi)∑ Si − 1
)
× 100
 
(6)
where, Si=i th segment lengths (i=1, 2, 3, …, n), APCi=i th 
annual percentage change.
 Measuring socioeconomic inequality
Index of Economic Resources (IER) was measured in 
quintiles, with the first quintile (Q1) representing the 
lowest 20% of the total population living in the most 
impoverished socioeconomic areas, and the fifth quin-
tile (Q5) representing the top 20% of the total popula-
tion living in the most prosperous socioeconomic areas. 
Inequality analyses were constructed for cancer incidence, 
cancer- related mortality and DALYs across the different 
IER quintiles. The absolute and relative differences (eg, 
least advantaged- most advantaged difference, LMD and 
least advantaged- most advantaged ratio, LMR) in cancer 
incidence, cancer- related mortality, YLL, YLD and DALY 
were calculated to examine the magnitude and direction 
of the cancer outcomes across different socioeconomic 
groups. A high value of the LMR and LMD represents 
a high degree of socioeconomic inequality.16 The ratio 
of cancer mortality and incidence (M/I) was measured 
to capture the survival inequality of cancer patients. The 
measures of the concentration index (CI) (Erreygers’ CI) 
was used to examine the magnitude of socioeconomic 
inequality and the trends in adverse cancer outcome 
changes during the period.50
 Multivariate analysis
The fatal cancer burden (eg, YLL) was considered as the 
outcome variable in the analytical exploration. YLL is 
characterised by a large cluster of data and a right- skewed 
distribution, but the zero values were excluded from the 
analysis. The natural logarithm of YLL was used to reduce 
the effects of the skewed nature of the burden of cancer 
data. In the multivariate analysis, natural logged YLL was 
predicted using different patients’ characteristics related 
to demographics (eg, sex), state, socioeconomic position 
and geographical distribution (eg, remoteness). A gener-
alised linear model (GLM) was constructed to examine 
these associations. The model was tested for sensitivity by 
including and excluding specific variables and estimating 
the robust SEs. A series of diagnostic tests were performed, 
such as tests on the presence of heteroscedasticity, multi-
collinearity and omitted variables. The Breusch- Pagan/
Cook- Weisberg test was used to check the presence of 
heteroscedasticity in the model. Variance Inflation Factor 
test was performed to examine the presence of multicol-
linearity. The Ramsey Ramsey Regression Equation Spec-
ification Error Test (RESET) test was to check if there is 
any omitted variable bias in the model. The outcome of 
the GLM analysis is presented as adjusted regression coef-
ficients with robust SEs along with 95% CIs. Data manage-
ment and all statistical analyses were performed using 
Stata/SE 13.0 (StataCorp, College Station, Texas, USA). 
A p value <0.05 was considered statistically significant.
ethics
This study was conducted using the publicly accessible 
AIHW online data sources and cancer- related published 
reports. Ethical approval was not required from an insti-
tutional review board because the patient information 
was de- identified.
Patient and public involvement
Patient and public were not involved in the design or 
planning of this study.
results
 trends in cancer incidence and cancer-related mortality
The overall incidence of cancer among males significantly 
increased from 1982 to 1994, and then increased expo-
nentially until 2014 (figure 1). The rate of cancer inci-
dence among females also showed an increasing trend 
from 1982 to 2014. The cancer incidence rate increased 
from 1984 (2507 cases) to 1991 (3896 cases) in South 
Australia, after which the rate increased slightly during 
the period 1992 (3994 cases) to 2002 (4127 cases), and 
then increased again until 2014 (5392 cases). A similar 
trend was observed for males in New South Wales and 
Western Australia. A sharp reduction of cancer inci-
dence was seen during 1994 (1333 cases) to 1997 (1100 
cases), and the overall rate increased during 1998 to 2008 
(1124 cases to 1889 cases) in Tasmania. In the Northern 
Territory and Australian Capital Territory, the incidence 
of cancer increased exponentially for both males and 
females throughout the period. The overall cancer- 
related mortality rate also increased for both males (eg, 
5000 cases in 1982 to 8470 cases in 2014) and females (eg, 
3952 cases in 1982 to 6490 cases in 2014) in New South 
Wales from 1982 to 2014. Further, a similar trend was 
observed for male and female in Victoria, Queensland, 
Western Australia, South Australia and Tasmania during 
the period 1982 to 2014 (figure 2). However, in the 
Northern Territory and Australian Capital Territory, little 
change from the trend was observed.
 distribution of average annual percentage change in cancer 
incidence and cancer-related mortality
Cancer incidence was measured as an AAPC over the 
period 1982 to 2014 (figure 3). Cancer incidence 
increased by an AAPC of 1.33% over the period 1982 
to 2014, with the AAPC slightly higher for males 1.38% 
compared with females 1.29%. The highest AAPC was 
found in Northern Territory (2.57%), followed by 
the Australian Capital Territory (1.78%) and Western 
Australia (1.65%). In NewSouth Wales (NSW), the rate 
of cancer incidence increased steadily from 1982 to 1994 
and then oscillated until 2013. Similarly, the percentage 
change of cancer incidence rate increased among females 
over time. Cancer mortality rate rose 0.76% from 1982 
to 2014, and the mortality rate among females (0.78%) 
was slightly higher compared with males (0.73%). In 
the Northern Territory, cancer- related mortality rate was 
comparatively very high among males (1.98%), while 
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Figure 1 Trends of cancer incidence by sex and state, Australia, 1982 to 2014. ACT,Australian Capital Territory; NSW, New 
South Wales; NT, Northern Territory;QLD, Queensland; SA, South Australia; WA, Western Australia.
cancer- related mortality rates were found to be compara-
tively highest among females in Queensland (1.21%) and 
Australian Capital Territory (1.13%).
 trends in cancer-related hospitalisation
A total of 13 213 340 cancer- related hospitalisation cases 
were observed, of which 66.91% were for same- day 
treatment and 33.09% were overnight hospitalisations 
(figure 4). The AAPC of overall cancer- related hospital-
isations increased by 1.27% as a whole, wherein same- day 
and overnight were 1.35% and 1.19%, respectively, 
higher over the period. The overnight hospitalisation 
rate fell over the period with a comparative increase in 
the same- day hospitalisation rate.
 trends in fatal cancer burden
An upward trend of the fatal burden of cancer was 
observed over the 2011 to 2015 period (figure 5). Males 
experienced a relatively higher burden (AAPC=0.89%) 
compared with females (AAPC=0.78%). The magnitude 
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Figure 2 Trends of cancer mortality by sex and state, Australia, 1982 to 2014. ACT,Australian Capital Territory; NSW, New 
South Wales; NT, Northern Territory;QLD, Queensland; SA, South Australia; WA, Western Australia.
of the burden also varied across the states. For example, 
the rate of years of life lost increased by 9950 YLL 
(AAPC=1.16%) in Queensland, 2612 YLL (AAPC=0.22%) 
in NSW, 5838 YLL (AAPC=1.42%) in WesternAustralia, 
2034 YLL (AAPC=0.63%) in SouthAustralia and 1253 
YLL (AAPC=2.57%) in the AustralianCapital Territory. A 
major reduction in the fatal burden of cancer occurred 
among females (11 339 YLL, AAPC=−1.53%) in Tasmania 
and for males (3532 YLL, AAPC=−0.72%) in Victoria.
 the magnitude of socioeconomic inequality for cancer 
patients
Cancer incidence was highest among the poorest quin-
tile (table 2). Similarly, the age- specific cancer incidence 
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Figure 3 Distribution of cancer outcomes in Australia, 1982 to 2014.
Figure 4 Distribution of cancer- related hospitalisations by same- day and overnight status in Australia, 2000 to 2015. 
AAPC, average annual percentage change; ACT, AustralianCapital Territory; NSW, New South Wales; NT, Northern Territory; 
QLD,Queensland; SA, South Australia; TAS, Tasmania; VIC, Victoria; WA, WesternAustralia.
was marginally highest among the poorest group. 
Furthermore, the poorest were 1.083 times more likely 
to be exposed to cancer than the richest and the poor/
rich difference amounted to an additional 9873 cases 
per year. The cancer- related mortality rate difference 
was even starker with the LMR (1.513 times) and LMD 
(17 770 cases/100 000 persons). The overall ratio of 
(LMR of mortality) and (LMR of incidence) was high 
(M/I=1.276). Again, it has been revealed that nearly 
34% more least advantaged group of people experienced 
cancer- related mortality compared with most advantaged 
economic resources of people. The overall magnitude of 
cancer incidence (CI=−0.029, p<0.01) and cancer- related 
mortality rate (CI=−0.011, p<0.05) were highest in the 
least advantaged group.
This skewed distribution was also true for the individual 
types or sites of cancer (table 3). The highest contribu-
tors to the socioeconomic inequality- mortality gap were 
colorectal (LMR=1.327 times), pancreas (LMR=1.336 
times), lung (LMR=1.965 times), cervix (LMR=1.363 
times), kidney (LMR=1.344 times), bladder (LMR=1.433 
times) and unknown primary cancer (LMR=1.660 times). 
Further, the ratio (LMR of mortality) and (LMR of 
incidence) was especially high for cervix (M/I=1.802), 
prostate (M/I=1.514), melanoma (M/I=1.325), non- 
Hodgkin's lymphoma (M/I=1.325) and breast (M/
I=1.318), suggesting that survival inequality was most 
pronounced for these cancers. The high value of the 
concentration index (CI) of different cancers, such 
as lung (CI=−0.060), melanoma (CI=−0.087), breast 
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Figure 5 Trends of fatal burden of cancer across states, Australia, 2011 to 2015.
(CI=−0.104), prostate (CI=−0.076) and non- Hodgkin's 
lymphoma (CI=−0.078), indicates that cancer inci-
dence was disproportionately distributed in the least 
economic resources quintile. In addition, a high degree 
of inequality in cancer related- mortality occurred across 
the different economic resources quintiles. Significant 
negative CI of mortality by different types of cancer, 
such as lung (CI=−0.066), melanoma (CI=−0.034), breast 
(CI=−0.048), cervix (CI=−0.095) and unknown primary 
cancer (CI=−0.043), reflected that mortality due to these 
types of cancers was more highly concentrated among the 
least advantaged economic resources group. Likewise, 
the number of deaths related to all types of cancer was 
highest among the least advantaged group. As a result, 
LMR is more than 1, and LMD is positive for all types of 
cancer- related mortality.
The magnitude of the fatal burden of cancer increases 
with a decline of the socioeconomic status of cancer 
patients (table 4). A notable difference was observed in 
the distribution of the fatal burden of cancer between 
the least advantaged and most advantaged quintiles. In 
2011, people in the least advantaged quintile experi-
enced high YLL (LMR=1.50 times, LMD=62.00 YLL/1000 
persons) compared with the richest quintile, and it 
had increased again slightly by 2015 (LMR=1.57 times, 
LMD=66.00 YLL/1,000 persons). The annual rate of 
years of life lost declined constantly (AAPC=−0.87%) 
across different quintiles over the period, and the rate 
of reduction was greatest in the most advantaged quin-
tile (AAPC=−1.69%) compared with the least advantaged 
quintile (AAPC=−0.63%). The fatal burden of all cancers 
was found to be highest in the least advantaged quintile 
(table 5). The annual reduction rate of cancer burden 
was highest in the most advantaged quintile compared 
with the least advantaged quintile. People diagnosed with 
cancer from the least advantaged economic resources 
areas bear a significant share of the total fatal burden 
(25%) compared with people from the most advantaged 
quintile (15%) (online supplementary appendix figure 
A1). However, a reduction in the share of fatal burden of 
cancer has been observed across all quintiles except the 
second quintile (AAPC=0.65% for Q2).
 Factors influencing the fatal burden of cancer
The regression coefficients were interpreted as the effect 
of a 1% change in the characteristics of cancer patients on 
the 1% change in YLL (table 6). These results show that 
a 1% increase in the proportion of male cancer patients 
slightly increased the YLL from 3.87% to 4.19%. In very 
remote areas the YLL increased by 32.05% in 2011 but 
reduced in 2015 by 22.75%.
However, the cancer burden was significantly increased 
for those who lived in remote, inner or outer regional 
areas during the period. In terms of geographical distribu-
tion, patients from New South Wales (32%) experienced 
a significantly higher burden, followed by Victoria (30%) 
and Queensland (25%), but the changes were stable 
during this period. In Western Australia and Tasmania, 
the burden of cancer significantly increased, by 15.72% 
to 20.80% and 6.29% to 7.90%, respectively. However, 
the burden of cancer declined for others, including the 
Northern Territory from 3.77% to 2.43%, and South 
Australia from 18.65% to 16.65%. Similarly, the magni-
tude of the cancer burden increased for those in the least 
advantaged economic resource quintiles.
disCussiOn
This study aimed to reveal the trends in cancer inci-
dence, related mortality and cancer burden, as well as 
measure the magnitude of inequality in cancer mortality, 
incidence and DALYs during the period of 1982 to 
2014 in Australia. The study design was an incidence- 
based on from a health system perspective. Overall inci-
dence and mortality showed an upward trend over the 
period and the highest average increase in incidence 
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was found in the Northern Territory, Australian Capital 
Territory and Western Australia. Also, the proportion of 
cancer- related hospitalisation has increased and is domi-
nated by same- day hospitalisations. Further, the survival 
inequality in terms of LMR of mortality and LMR of 
incidence was especially high for prostate, cervix, mela-
noma, non- Hodgkin's lymphoma and breast, suggesting 
that survival inequality was most pronounced for these 
cancers. Overall, the fatal burden of cancer exhibited an 
increasing trend over the period.
The study’s findings support a growing body of 
research evidence that has found the incidence of cancer 
and cancer- related mortality to be increasing in other 
country settings.14 51–54 These increasing trends have been 
pronounced in the last couple of decades globally.6 52 53 The 
WHO55 and the Sustainable Development Goals56 have 
outlined the increasing burden of non- communicable 
diseases that include cancer, and have promoted initia-
tives to control and prevent future increases through 
action plans. Still, the burden of cancer has been growing 
in Australia over the last decades.24 Four driving forces 
have contributed to this: first, increased exposure to risk 
factors (for example, unbalanced and industrialised- type 
diets)57 as well as a high prevalence of obesity58 59; second, 
improved health outcomes (eg, life expectancy)4 and 
demographic transition (eg, ageing and growth of popu-
lation)5 has reduced death rates compared with other 
causes of death; third, widespread urbanisation (respon-
sible for the change in lifestyles),60 exposure to smoking61 
and alcohol consumption60 are contributing to devel-
oping higher cancer risk60 62 and fourth, overdiagnosis is 
considered another potential driving force for increasing 
cancer incidence and related mortality. It is evident from 
past studies that overdiagnosis has played a significant role 
in increasing the burden of cancer63 but that the rising 
magnitude of cancer burden among Australians may 
not be entirely explained by overdiagnosis.64 Therefore, 
further research that explores the potential risk factors 
may contribute to a deeper understanding of the reasons 
behind the increasing burden of cancer in Australia.
This study found that survival inequality was most 
pronounced for prostate cancers and consistent with 
previous studies.65 66 Evidence about underlying causes 
to explain inequalities in prostate cancer. Some possible 
explanations can be considered such as factors associated 
with the tumour (eg, stage at diagnosis, biological char-
acteristics), the patient (comorbidity, health behaviour, 
psychosocial factors) and the healthcare (treatment, 
medical expertise, screening).65–67 Furthermore, the util-
isation rate of screening services is lower among pros-
tate cancer patients with disadvantaged socioeconomic 
status.68 69 Moreover, patient factors as comorbidity or 
health behaviour can interact with treatment modalities 
or disease stage and additionally have a potential impact 
on inequalities in survival.70 71 Further, an increased 
likelihood of surveillance as treatment among patients 
with severe comorbidity while radical prostatectomy was 
significantly less likely to be offered.65 66 69 70 Some studies 
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Table 6 Association of fatal cancer burden (natural logged of years of life lost) with sex, remoteness, location and 
socioeconomic resources
Variables
Model 1 Model 2
Coefficient
(SE) P value 95% 
Coefficient
(SE) P value 95% 
Sex
  Male 0.038 (0.034) 0.01 (0.014 to 0.088) 0.041 (0.026) 0.010 (0.011 to 0.091)
  Female (ref) ref – – ref – –
Remoteness
  Major cities (ref) ref – – ref – –
  Inner regional 0.042 (0.002) <0.001 (0.014 to 0.080) 0.100 (0.003) <0.001 (0.025 to 0.174)
  Outer regional 0.149 (0.007) <0.001 (0124 to 0.158) 0.158 (0.001) <0.001 (0.103 to 0.253)
  Remote 0.158 (0.006) <0.001 (0.113 to 0.246) 0.189 (0.004) <0.001 (0.149 to 0.343)
  Very remote 0.278 (0.009) <0.001 (0.211 to 0.344) 0.205 (0.002) <0.001 (0.131 to 0.379)
Location (States)         
  Australian Capital Territory (ref) ref – – ref – –
  New South Wales 0.282 (0.008) <0.001 (0.187 to 0.376) 0.278 (0.008) <0.001 (0.184 to 0.372)
  Northern Territory 0.037 (0.009) 0.336 (−0.039 to 0.113) 0.024 (0.004) 0.560 (−0.055 to 
0.103)
  Queensland 0.234 (0.008) <0.001 (0.139 to 0.327) 0.223 (0.005) <0.001 (0.125 to 0.321)
  South Australia 0.171 (0.005) <0.001 (0.084 to 0.258) 0.154 (0.005) <0.001 (0.065 to 0.243)
  Tasmania 0.061 (0.004) 0.167 (−0.026 to 0.148) 0.076 (0.002) 0.070 (−0.007 to 
0.158)
  Victoria 0.268 (0.005) <0.001 (0.179 to 0.357) 0.263 (0.005) <0.001 (0.174 to 0.351)
  Western Australia 0.146 (0.009) <0.003 (0.048 to 0.244) 0.189 (0.004) <0.001 (0.104 to 0.275)
Index of economic resources         
  Q1 (least advantaged) 0.063 (0.002) 0.032 (0.019 to 0.146) 0.073 (0.004) 0.040 (0.032 to 0.159)
  Q2 0.042 (0.004) 0.331 (−0.043 to 0.128) 0.046 (0.007) 0.320 (−0.045 to 
0.138)
  Q3 0.039 (0.001) 0.343 (−0.042 to 0.120) 0.042 (0.004) 0.330 (−0.044 to 
0.128)
  Q4 0.011 (0.003) 0.795 (−0.073 to 0.096) 0.010 (0.005) 0.830 (−0.079 to 
0.098)
  Q5 (most advantaged) ref – – ref – –
Constant 0.931 (0.004) <0.001 (0.885 to 0.978) 0.899 (0.008) <0.001 (0.864 to 0.935)
Family distribution Gaussian distribution Gaussian distribution
Link function Identity Identity
Deviance   25.13   14.85
Link- test (beta hat) 0.110 (0.018) <0.001 (0.075 to 0.145) 0.103 (0.008) <0.001 (0.087 to 0.119)
AIC 1.07 1.02
BIC 2.92 3.05
Note: Models 1 and 2 were constructed for 2011 and 2015, respectively; ref=reference group.
AIC, Akaike information criterion; BIC, Bayesian information criterion.
conducted in England,72 Australia73 and the USA74 also 
revealed that socioeconomically disadvantaged patients 
have a reduced likelihood of having radical prostatec-
tomy compared with patients with disadvantaged socio-
economic status who utilised more regularly hormone 
therapy, active surveillance, watchful waiting and partly 
radiation. There is an ongoing debate regarding the signif-
icant role of healthcare management as a contributing 
factor to inequalities in survival among prostate cancer 
patients.67
The results show that the overall incidence, cancer- 
related mortality and cancer burden (eg, YLL, YLD and 
DALYs) were significantly higher among the least advan-
taged group compared with the most advantaged. It was 
also found that the least advantaged quintile on average 
experienced 34% more cancer- related mortality than 
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their most advantaged counterparts. Similarly, patients 
in the least advantaged group experienced a significantly 
higher burden of cancer in terms of YLL (6.50% to 7.57%) 
compared with the richest (1.11%) from 2011 to 2015. 
Previous studies have also reported similar inequalities 
in YLL,75 76 whereas, a high proportion of patients in the 
most- deprived groups experienced very high years loss of 
life. Even though survival rates after cancer diagnosis have 
improved in recent years,7 disparities in cancer outcomes 
between the least- deprived and the most- deprived groups 
continue to persist. The magnitude of the cancer burden 
is negatively associated with socioeconomic status.77–80 For 
example, adverse health outcomes (eg, worse health status 
and shorter life expectancy) are disproportionately found 
in poorer people compared with those in higher quin-
tiles.77–80 Some reasons that have contributed to the high 
rate of cancer burden among the poorest groups includes 
smoking exposure,51 77 poverty and economic burden,61 81 
increased psychological pressure,3 lack of health educa-
tion and awareness82 and lower access to competent and 
effective public health interventions.82 There are several 
factors which lead to increased breast cancer incidence 
and cancer- related mortality. These can be classified into 
patients, tumour and treatment characteristics.83–85 These 
characteristics include patient age, ethnicity, tumour 
type, size, grade, stage, hormone receptor status, type of 
surgery and the use of adjuvant therapies.83–85 A recent 
review study demonstrated that treatment‐related factors 
and socioeconomic disadvantage are also responsible for 
high cancer burden in Australia.84
Moreover, low productivity, loss/reduction of house-
hold income and increased expenditure due to illness 
result in reduced earnings and higher expenditure that 
further disadvantage the poorest. Growing socioeco-
nomic inequalities of cancer outcomes need the atten-
tion of governments, health systems and decision- makers. 
These initiatives should aim for universal cancer care 
in all states. A sustained reduction of socioeconomic 
inequalities, which concerns poverty, gender, education 
and health, should promote universal equality in health 
and well- being and further enhance both socioeconomic 
and human development.
The present study has also identified that the fatal 
burden of cancer was high in 2011 among patients in very 
remote areas, but it was reduced by 2015. Similarly, the 
burden of cancer was high in New South Wales, Victoria 
and Queensland; however, the magnitude of fatal burden 
was unchanged during 2011 to 2015. Some previous 
studies have shown consistent findings, which have 
confirmed that the proportion of life lost for patients 
in geographical disadvantaged or low- resource settings 
had a higher cancer burden than their more advantaged 
counterparts.75 76 Socioeconomic inequalities in terms of 
poorer survival for geographically isolated patients was 
observed in cancer types in Australia including breast 
and colorectal cancer.86 Several issues might be asso-
ciated with a high burden of cancer among patients 
in regional and remote Australia, including a lack of 
appropriate skills among health professionals and a lack 
of adequate resources being available in remote and 
smaller cities.15 33 87 A recent study conducted in regional 
Australia identified that there was a paucity of medical 
professionals with expertise and appropriate cancer 
training in regional areas.68 The study also confirmed 
that a lack of communication and coordination persisted 
between different medical professionals (such as oncolo-
gists and GPs) and across geographical locations (major 
vs regional centres).
Difficulty in service accessibility and availability of 
appropriate cancer care services is faced by residents of 
rural, remote communities in Australia.87 However, only 
30% of the population lives outside the major cities.88 
The federal government has committed to improving the 
cancer infrastructure by building a network of new and 
enhanced regional cancer centres in regional Australia.89 
Furthermore, innovative cancer care models, including 
mobile clinics incorporating video conference and tele- 
oncology, have been introduced in order to address 
the challenges of distance. Advanced technology- based 
services such as tele- oncology have been implemented 
in Western Australia and North Queensland, allowing 
regional cancer patients to use the latest treatments 
including specialist consultations and chemotherapy 
treatments.90 91 These models have also been imple-
mented in the USA and Canada to ensure maximum 
access to services among people in limited resources 
settings, with high levels of satisfaction and acceptance 
of services.90–94
This study contributes to the existing literature by 
providing first- hand evidence on the trends of incidence, 
mortality and burden of cancer, using Australian nation-
ally representative population- based data. This study has 
used large national level data sets covering all states over 
the past 33 years. Due to paucity of survival data, this 
study has not captured in details inequalities regarding 
the cancer survivorship. However, there is a limited 
understanding of what is driving these changes of cancer 
outcomes reported here which may reflect random vari-
ation or changes in unknown risk factors, and therefore 
highlight the need for more research into the aetiology 
of cancer.
COnClusiOns
The overall burden of cancer is substantial in Australia 
across all socioeconomic strata and geographical regions. 
Compared with socioeconomically advantaged people, 
disadvantaged people had a substantially higher risk of 
cancer incidence and cancer- related mortality. Those 
living in remote areas also bear a higher burden than 
those in urban areas who are closer to prevention and 
treatment services. The findings of this study can inform 
efforts by healthcare policymakers and those involved in 
healthcare systems to improve cancer survival in Australia. 
This work also suggests that the provision of universal 
cancer care can reduce the burden by ensuring curable 
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and preventive cancer care services are accessible for all 
people regardless of socioeconomic status or location.
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